Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-26-087508
Filing Date
2026-08-11
Accepted
2026-08-11 08:10:59
Documents
76
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0298600-10q_protara.htm   iXBRL 10-Q 1007794
2 THIRD CERTIFICATE OF AMENDMENT TO THE SIXTH AMENDED AND RESTATED CERTIFICATE OF ea029860001ex3-4.htm EX-3.4 10340
3 COMPOSITE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY ea029860001ex3-7.htm EX-3.7 50526
4 AMENDMENT NO. 1 TO THE COMPANY'S 2024 EQUITY INCENTIVE PLAN, AS AMENDED ea029860001ex10-1.htm EX-10.1 4674
5 CERTIFICATION ea029860001ex31-1.htm EX-31.1 10410
6 CERTIFICATION ea029860001ex31-2.htm EX-31.2 10162
7 CERTIFICATION ea029860001ex32-1.htm EX-32.1 5090
  Complete submission text file 0001213900-26-087508.txt   5613803

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE tara-20260630.xsd EX-101.SCH 56805
9 XBRL CALCULATION FILE tara-20260630_cal.xml EX-101.CAL 42153
10 XBRL DEFINITION FILE tara-20260630_def.xml EX-101.DEF 225104
11 XBRL LABEL FILE tara-20260630_lab.xml EX-101.LAB 472757
12 XBRL PRESENTATION FILE tara-20260630_pre.xml EX-101.PRE 261985
80 EXTRACTED XBRL INSTANCE DOCUMENT ea0298600-10q_protara_htm.xml XML 709824
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

EIN.: 204580525 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36694 | Film No.: 261260706
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)